Mizuho Securities Cuts Price Target on Myriad Genetics (MYGN) to $22 Following 4Q and Guidance

Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q

August 11, 2016 8:37 AM EDT

Jefferies maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $20.00 (from $34.00), following the company's 4Q earnings report. The company's weaker 4Q16 experience (-7%) and initial FY17 outlook for the HC segment (-7%) suggest pricing and... More

Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform

August 10, 2016 7:03 AM EDT

Wells Fargo downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $29.46 yesterday.

... More

Piper Jaffray Downgrades Myriad Genetics (MYGN) to Neutral

August 10, 2016 6:38 AM EDT

Piper Jaffray downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Neutral with a price target of $22.00 (from $47.00).

Analyst William Quirk commented, "Myriad's 4Q16 revenue declined 1.8% yoy to $186.5M, below our in line estimate of $187.7M. EPS of $0.36 was below our in line $0.37 estimate.... More

After-Hours Stock Movers 08/09: (CLNE) (OCN) (YELP) Higher; (GEVO) (SPWR) (MYGN) Lower (more...)

August 9, 2016 6:01 PM EDT

Today's After-Hours Movers

Gevo (NASDAQ: GEVO) 30% LOWER; reported Q2 EPS of ($0.15), versus ($0.66) reported last year. Revenue for the quarter came in at $8.11 million, versus $8.9 million reported last year.

SunPower (NASDAQ: SPWR) 30% LOWER; reported Q2 EPS of ($0.22), $0.02 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $420.5 million versus the consensus estimate of $345.08 million. GUIDANCE: SunPower sees FY2016 revenue of $3-3.2... More

Myriad Genetics (MYGN) Misses Q4 EPS by 6c; Issues Weak Q1, FY17 Outlook

August 9, 2016 4:11 PM EDT

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.32, $0.06 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $187.92 million.

GUIDANCE:

Myriad Genetics sees Q1 2017 EPS of $0.25-$0.27, versus the consensus of... More

Myriad Genetics (MYGN) halted with news pending

August 9, 2016 4:00 PM EDT

Myriad Genetics (NASDAQ: MYGN) halted with news pending.

... More

Trading Radar for 8/9: Disney (DIS), Coach (COH), Valeant Pharma (VRX), Wayfair (W), Yelp (YELP) Report

August 8, 2016 2:26 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EDT

Productivity: Prelim. - Street sees 0.5%Unit Labor Costs - Street sees 1.7%

Earnings:

AECOM Technology (NYSE: ACM) - consensus EPS $0.70
AMAG Pharma (Nasdaq: AMAG) - consensus EPS $1.20
Adesto Technologies Corporation (Nasdaq: IOTS) - no Street consensus
AerCap Holdings (NYSE: AER) - consensus EPS $1.48
AgroFresh Solutions (Nasdaq:... More